{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:08:07Z","timestamp":1787238487184,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior Reports"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ebr.2020.100409","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T12:09:43Z","timestamp":1606306183000},"page":"100409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["The unmet need for rapid epileptic seizure termination (REST)"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5625-6126","authenticated-orcid":false,"given":"Aviva","family":"Asnis-Alibozek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8334-1403","authenticated-orcid":false,"given":"Kamil","family":"Detyniecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ebr.2020.100409_b0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/ern.12.151","article-title":"Epilepsy therapy: anticonvulsants, lessons learned and unmet medical needs","volume":"13","author":"Klitgaard","year":"2013","journal-title":"Expert Rev Neurother"},{"issue":"suppl 4","key":"10.1016\/j.ebr.2020.100409_b0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/epi.12296","article-title":"Issues related to the development of new antiseizure treatments","volume":"54","author":"Wilcox","year":"2013","journal-title":"Epilepsia"},{"issue":"15","key":"10.1016\/j.ebr.2020.100409_b0015","doi-asserted-by":"crossref","first-page":"437","DOI":"10.15585\/mmwr.mm6715a1","article-title":"Active epilepsy and seizure control in adults \u2014 United States, 2013 and 2015","volume":"67","author":"Tian","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ebr.2020.100409_b0020","doi-asserted-by":"crossref","unstructured":"Bonnet LF, Powell GA, Smith CT, et al. Breakthrough seizures \u2013 further analysis of the standard versus new antiepileptic drugs (SANAD) study. PLoS ONE. 2017;12(12):e0190035.","DOI":"10.1371\/journal.pone.0190035"},{"key":"10.1016\/j.ebr.2020.100409_b0025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-94-017-8914-1_9","article-title":"When and how do seizures kill neurons, and is cell death relevant to epileptogenesis?","volume":"813","author":"Dingledine","year":"2014","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ebr.2020.100409_b0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.seizure.2018.05.013","article-title":"Seizure cluster: definition, prevalence, consequences, and management","volume":"68","author":"Jafarpour","year":"2019","journal-title":"Seizure"},{"issue":"12","key":"10.1016\/j.ebr.2020.100409_b0035","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1528-1157.1999.tb01607.x","article-title":"The association between seizure clustering and convulsive status epilepticus in patients with intractable complex partial seizures","volume":"40","author":"Haut","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2020.100409_b0040","unstructured":"Diastat [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2016."},{"key":"10.1016\/j.ebr.2020.100409_b0045","unstructured":"Valtoco [package insert]. San Diego, CA: Neurelis, Inc.: 2020."},{"key":"10.1016\/j.ebr.2020.100409_b0050","unstructured":"Nayzilam [package insert]. Smyma, GA: UCB, Inc.: 2019."},{"issue":"10","key":"10.1016\/j.ebr.2020.100409_b0055","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition of status epilepticus \u2013 report of the ILAE task force on classification of status epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2020.100409_b0060","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.seizure.2016.11.001","article-title":"25 years of advances in the definition, classification and treatment of status epilepticus","volume":"44","author":"Trinka","year":"2017","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.ebr.2020.100409_b0065","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr."},{"issue":"8","key":"10.1016\/j.ebr.2020.100409_b0070","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/epi.16279","article-title":"Inhaled alprazolam rapidly suppresses epileptic activity in photosensitive participants","volume":"60","author":"French","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2020.100409_b0075","unstructured":"Biton V, French J, Dave H, et al. A two-part, phase 2b efficacy study of Staccato\u00ae alprazolam inhaler in patients with epilepsy with a predictable seizure pattern: Topline results from part 2. In Paper presented at: American Academy of Neurology Annual Meeting. April 25-May1, 2020; Toronto, Canada (meeting canceled due to COVID-19). https:\/\/index.mirasmart.com\/AAN2020\/PDFfiles\/AAN2020-000676.html. Accessed June 12, 2020."},{"issue":"4","key":"10.1016\/j.ebr.2020.100409_b0080","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: position Paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2020.100409_b0085","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.yebeh.2015.06.013","article-title":"Clinical and economic burden of breakthrough seizures","volume":"51","author":"Divino","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2020.100409_b0090","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/epi.14479","article-title":"Rescue therapies for seizure emergencies: new modes of administration","volume":"59","author":"Maglalang","year":"2018","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.ebr.2020.100409_b0095","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/epi.15159","article-title":"Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters\u2014a randomized, double\u2010blind, placebo\u2010controlled trial","volume":"60","author":"Detyniecki","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2020.100409_b0100","doi-asserted-by":"crossref","first-page":"106537","DOI":"10.1016\/j.yebeh.2019.106537","article-title":"Diazepam buccal film for the treatment of acute seizures","volume":"101","author":"Rogawski","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2020.100409_b0105","unstructured":"Sympazan [package insert]. Warren, NJ: Aquestive Therapeutics: 2018."},{"issue":"11","key":"10.1016\/j.ebr.2020.100409_b0110","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/epi.16696","article-title":"Safety and tolerability associated with chronic intermittent use of diazepam buccal film in adult, adolescent, and pediatric patients with epilepsy","volume":"61","author":"Seinfeld","year":"2020","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.ebr.2020.100409_b0115","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJMoa1107494","article-title":"Intramuscular versus intravenous therapy for prehospital status epilepticus","volume":"366","author":"Silbergleit","year":"2012","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ebr.2020.100409_b0120","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","article-title":"Randomized trial of three anticonvulsant medications for status epilepticus","volume":"381","author":"Kapur","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebr.2020.100409_b0125","unstructured":"European Medicines Agency (EMA). European Medicines Agency gives first positive opinion for pediatric-use marketing authorization. EMA. https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/european-medicines-agency-gives-first-positive-opinion-paediatric-use-marketing-authorisation_en.pdf. Published June 24, 2011. Accessed September 1, 2020."},{"key":"10.1016\/j.ebr.2020.100409_b0130","unstructured":"Buccolam [summary of product characteristics]. Brussels, Belgium: Shire Services BVBA; 2019."},{"issue":"5","key":"10.1016\/j.ebr.2020.100409_b0135","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/epi.14069","article-title":"Determination of minimal steady\u2010state plasma level of diazepam causing seizure threshold elevation in rats","volume":"59","author":"Dhir","year":"2018","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.ebr.2020.100409_b0140","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/j.1528-1167.2006.00622.x","article-title":"How long do most seizures last? A systematic comparison of seizures recorded in the epilepsy monitoring unit","volume":"47","author":"Jenssen","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2020.100409_b0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.brainres.2018.02.032","article-title":"Patterns of epileptic seizure occurrence","volume":"1703","author":"Amengual-Gual","year":"2019","journal-title":"Brain Res"},{"issue":"2","key":"10.1016\/j.ebr.2020.100409_b0150","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s13311-013-0243-0","article-title":"Effects of marketed antiepileptic drugs and placebo in the human photosensitivity screening protocol","volume":"11","author":"French","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ebr.2020.100409_b0155","unstructured":"French JA, Gelfand M, Vazquez B, Reich B, Isojarvi J. Stacatto alprazolam for the treatment of epilepsy. Poster presented at: Park City Epilepsy Meeting; October 6-8, 2019; Park City, UT."},{"key":"10.1016\/j.ebr.2020.100409_b0160","unstructured":"Engage Therapeutics announces phase 2b StATES study of Staccato alprazolam for seizure cessation meets primary endpoint. Engage Therapeutics. https:\/\/engagetherapeutics.com\/wp-content\/uploads\/2020\/03\/Engage-Staccato-Alprazolam-Phase-2b.pdf. Published March 12, 2020. Accessed August 25, 2020."},{"issue":"1","key":"10.1016\/j.ebr.2020.100409_b0165","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s12325-016-0452-0","article-title":"Efficacy of a novel prefilled, single-use, needle-free device (Zeneo\u00ae) in achieving intramuscular agent delivery: an observational study","volume":"34","author":"Bardou","year":"2017","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.ebr.2020.100409_b0170","doi-asserted-by":"crossref","first-page":"52","DOI":"10.23736\/S0031-0808.18.03423-7","article-title":"Human factors study of Zeneo\u00ae (needle-free autoinjector) and comparison of different user instruction formats","volume":"60","author":"Allaert","year":"2018","journal-title":"Panminerva Med"},{"issue":"4","key":"10.1016\/j.ebr.2020.100409_b0175","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/03007995.2016.1263611","article-title":"Single-center, single-dose, open-label, randomized, two-period crossover study on the bioavailability of methrotrexate administered using a novel prefilled, needle-free delivery system","volume":"33","author":"Bienvenu","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ebr.2020.100409_b0180","unstructured":"Zeneo\u00ae midazolam earns the FDA Orphan Drug designation for the treatment of status epilepticus. Crossject. https:\/\/www.crossject.com\/sites\/default\/files\/2018-03\/Communiqu%C3%A9%20FDA%20Anglais.pdf. Published February 14, 2018. Accessed August 25, 2020."},{"key":"10.1016\/j.ebr.2020.100409_b0185","unstructured":"Laney J, Clark M. FDA approval of anti-seizure drug provides a new tool for protecting Americans during a chemical attack. The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND). https:\/\/www.jpeocbrnd.osd.mil\/news\/news-story\/2018\/10\/24\/fda-approval-of-anti-seizure-drug-provides-a-new-tool-for-protecting-americans-during-a-chemical-attack. Published October 24, 2018. Accessed August 31, 2020."},{"key":"10.1016\/j.ebr.2020.100409_b0190","unstructured":"Seizalam [package insert]. Lake Forest, IL: Hospira, Inc. (Meridian Medical Technologies): 2018."},{"key":"10.1016\/j.ebr.2020.100409_b0195","unstructured":"Lorazapam Injection [package insert]. Lake Forest, IL: Akorn, Inc.: 2020."},{"key":"10.1016\/j.ebr.2020.100409_b0200","unstructured":"Diazepam Injection, USP [package insert]. Lake Forest, IL: Hospira: 2019."}],"container-title":["Epilepsy & Behavior Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589986420300575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589986420300575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:06:35Z","timestamp":1762905995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589986420300575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":40,"alternative-id":["S2589986420300575"],"URL":"https:\/\/doi.org\/10.1016\/j.ebr.2020.100409","relation":{},"ISSN":["2589-9864"],"issn-type":[{"value":"2589-9864","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The unmet need for rapid epileptic seizure termination (REST)","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebr.2020.100409","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100409"}}